Warfarin anticoagulation for liver fibrosis in patients transplanted for hepatitis C virus infectio

Not Applicable

Completed

• Conditions: Prevention of liver fibrosis in patients who have received a liver transplant as a result of hepatitis C virus (HCV) infection; Digestive System

• Registration Number: ISRCTN12504151
• Lead Sponsor: Imperial College London (UK)

Brief Summary

2015 Abstract results in https://doi.org/10.1016/S0168-8278(15)30165-3 1-year interim results presented at the International Liver Congress (added 05/09/2023) 2011 Thesis results in https://doi.org/10.25560/9479 1-year interim results (added 05/09/2023)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2008-10-31
• Study Completion: 2012-07-01
• Last Update Posted: 18 September 2023

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 90

Inclusion Criteria

1. Hepatitis C virus (HCV) infection
2. Aged over 17 years, either sex
3. Liver transplant within previous 4 months
4. Informed consent

Exclusion Criteria

1. Patients requiring anticoagulation for existing clinical indications
2. Standard contraindications to anticoagulation (active peptic ulcer disease, past history of haemorrhagic stroke, thrombocytopaenia (platelets count less than 90 x10^9/L)
3. Large oesophageal varices persisting post-transplant
4. Cerebrovascular abnormalities on pre-transplant computed tomography (CT) scan
5. Human immunodeficiency virus (HIV) antibody positive

Study & Design

• Study Type: Interventional
• Study Design: Not specified